We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-3.54%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.7B
AUM Growth
+$696M
Cap. Flow
+$853M
Cap. Flow %
4.12%
Top 10 Hldgs %
37.98%
Holding
357
New
50
Increased
42
Reduced
43
Closed
37

Sector Composition

Rank Sector Weight
1 Healthcare 30.5%
2 Technology 15.84%
3 Financials 13.74%
4 Industrials 11.78%
5 Communication Services 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PANA
151
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$7.33M 0.04%
750,000
RACB
152
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$7.32M 0.04%
750,000
ARYE
153
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$7.24M 0.04%
745,000
GIIX
154
DELISTED
Gores Holdings VIII, Inc. Class A Common Stock
GIIX
$6.89M 0.03%
692,810
KVSA
155
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
$6.85M 0.03%
700,000
STRE
156
DELISTED
Supernova Partners Acquisition Company III, Ltd.
STRE
$6.85M 0.03%
700,000
CORS
157
DELISTED
Corsair Partnering Corporation
CORS
$6.8M 0.03%
700,000
RCEL icon
158
Avita Medical
RCEL
$311M
$6.78M 0.03%
800,000
ARWR icon
159
Arrowhead Research
ARWR
$12.3B
$6.56M 0.03%
142,700
-177,917
-55% -$8.81M
COGT icon
160
Cogent Biosciences
COGT
$6.37B
$6.37M 0.03%
850,000
+250,000
+42% +$1.74M
RKTA
161
DELISTED
Rocket Internet Growth Opportunities Corp.
RKTA
$6.34M 0.03%
647,945
CLVR
162
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
$6.07M 0.03%
81,214
-20,448
-20% -$1.11M
THRX
163
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$6.04M 0.03%
523,979
RCFA
164
DELISTED
Perception Capital Corp. IV
RCFA
$5.96M 0.03%
+600,000
New +$5.93M
GBT
165
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.87M 0.03%
169,458
+83,004
+96% +$2.48M
FSRX
166
DELISTED
FinServ Acquisition Corp. II Class A Common Stock
FSRX
$5.86M 0.03%
600,000
IPVI
167
DELISTED
InterPrivate IV InfraTech Partners Inc. Class A Common Stock
IPVI
$5.85M 0.03%
600,000
BWC
168
DELISTED
Blue Whale Acquisition Corp I Class A Ordinary Shares
BWC
$5.58M 0.03%
575,000
SLAM
169
DELISTED
Slam Corp. Class A Ordinary Share
SLAM
$5.57M 0.03%
570,396
PNT
170
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$4.99M 0.02%
626,322
-1,080,007
-63% -$6.86M
GSQD
171
DELISTED
G Squared Ascend I Inc.
GSQD
$4.92M 0.02%
500,000
TIOA
172
DELISTED
Tio Tech A Class A Ordinary Share
TIOA
$4.92M 0.02%
502,001
HERA
173
DELISTED
FTAC Hera Acquisition Corp. Class A Ordinary Shares
HERA
$4.89M 0.02%
500,000
GHIX
174
DELISTED
Gores Holdings IX, Inc. Class A Common Stock
GHIX
$4.89M 0.02%
+500,000
New +$4.85M
CLAA
175
DELISTED
Colonnade Acquisition Corp. II
CLAA
$4.88M 0.02%
500,000

Similar funds

Thomas Steyer's Q1 2022 Portfolio in Review

As of Q1 2022, Thomas Steyer held 357 positions worth $20.7B, up 3.5% from $20B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Thomas Steyer deployed $853M of net new capital in Q1 2022, opening 50 new positions and adding to 42 existing holdings. Its largest new stake was ZYNGA INC. CL A COMMON: 44,475,000 shares worth $411M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was RTX Corp, an estimated $227M trimmed.

  • Thomas Steyer's largest Q1 2022 buy was ZYNGA INC. CL A COMMON: 44,475,000 shares worth $411M.
  • Thomas Steyer added most to TransUnion in Q1 2022, an estimated $345M increase.
  • Thomas Steyer's biggest Q1 2022 reduction was RTX Corp, cutting an estimated $227M.
  • Thomas Steyer fully exited Xilinx Inc in Q1 2022, selling an estimated $561M.
  • Thomas Steyer's ten largest holdings make up 38% of its $20.7B portfolio in Q1 2022.
  • Thomas Steyer opened 50 new positions and closed 37 in Q1 2022.
  • Thomas Steyer's portfolio value rose 3.5% quarter-over-quarter to $20.7B.

Based on Farallon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.